In-vitro NLRP3 functional test assists the diagnosis of cryopyrin-associated periodic syndrome (CAPS) patients: A Brazilian cooperation

Carregando...
Imagem de Miniatura
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
ACADEMIC PRESS INC ELSEVIER SCIENCE
Autores
Citação
CLINICAL IMMUNOLOGY, v.245, article ID 109159, 8p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective: To report our five-years experience on the use of NLRP3 inflammasome functional assays in the differential diagnosis of Brazilian patients with a clinical suspicion of CAPS. Patients and methods: The study included 9 patients belonging to 2 families (I, II) and 7 unrelated patients with a clinical suspicion of AID according to Eurofever/PRINTO classification, recruited between 2017 and 2022. The control group for the NLRP3 functional assay consisted of 10 healthy donors and for the CBA cytokines measurement of 19 healthy controls. Patients underwent clinical evaluation, genetic and functional analysis. Results: All members of the family I received the diagnosis of Muckle-Wells Syndrome (MWS), carried the NLRP3 Thr348Met variant and resulted positive for the functional assay. The 2 patients of the family II resulted negative for the mutational screening but positive for the functional assay compatible with a MWS clinical phenotype. In 2 unrelated patients with NLRP3 mutations, including a novel mutation (Gly309Val, Asp303His), a positive functional test confirmed the clinical diagnosis of NOMID. 3 unrelated MWS and 1 FCAS patients resulted negative to the genetic screening and positive for the functional test. One patient with a FCAS-like phenotype harbored the NLRP12 His304Tyr variant confirming the diagnosis of FCAS2. Conclusion: The NLRP3 inflammasome functional assay can assist the clinical diagnosis of CAPS even in patients with unknown genetic defects.
Palavras-chave
Autoinflammatory diseases, NLRP3, CAPS, Cryopirin-associated periodic syndrome
Referências
  1. Aksentijevich I, 2021, NAT REV RHEUMATOL, V17, P405, DOI 10.1038/s41584-021-00614-1
  2. Arostegui JI, 2004, ARTHRITIS RHEUM-US, V50, P4045, DOI 10.1002/art.20633
  3. Canna SW, 2014, NAT GENET, V46, P1140, DOI 10.1038/ng.3089
  4. Carta S, 2015, P NATL ACAD SCI USA, V112, P2835, DOI 10.1073/pnas.1424741112
  5. Gaggiano C, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/3293145
  6. Gattorno M, 2007, ARTHRITIS RHEUM, V56, P3138, DOI 10.1002/art.22842
  7. Gattorno M, 2019, ANN RHEUM DIS, V78, P1025, DOI 10.1136/annrheumdis-2019-215048
  8. Gusdorf L, 2020, J EUR ACAD DERMATOL, V34, P685, DOI 10.1111/jdv.15984
  9. Harapas CR, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926-018-0750-4
  10. Jeskey J, 2020, ALLERGY RHINOL, V11, DOI 10.1177/2152656720928062
  11. Jesus AA, 2012, J CLIN IMMUNOL, V32, P922, DOI 10.1007/s10875-012-9688-x
  12. Kelley N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133328
  13. Levy D, 2021, RMD OPEN, V7, DOI 10.1136/rmdopen-2021-001824
  14. Magnotti F, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910547
  15. Nakanishi H, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00141
  16. Rieber N, 2015, CLIN IMMUNOL, V157, P56, DOI 10.1016/j.clim.2015.01.003
  17. Rusmini M, 2016, ANN RHEUM DIS, V75, P1550, DOI 10.1136/annrheumdis-2015-207701
  18. Saito M, 2008, BLOOD, V111, P2132, DOI 10.1182/blood-2007-06-094201
  19. Tanaka N, 2011, ARTHRITIS RHEUM-US, V63, P3625, DOI 10.1002/art.30512
  20. Tangye SG, 2021, J CLIN IMMUNOL, V41, P666, DOI 10.1007/s10875-021-00980-1
  21. Van Gorp H, 2020, ANN RHEUM DIS, V79, P960, DOI 10.1136/annrheumdis-2019-216701
  22. Welzel T, 2021, J CLIN MED, V10, DOI 10.3390/jcm10010128